Business Context and Reporting Period
Sunshine Biopharma Inc. (SBFM) filed this Form 8-K on September 9, 2024, regarding a regulatory event with the Nasdaq Stock Market LLC. The Company is incorporated in Colorado and maintains its principal executive offices in Fort Lauderdale, Florida.
Key Financial Metrics
This filing is a Current Report under Item 8.01 (Other Events) and does not contain financial statements. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the Company's regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). This status follows a decision by the Nasdaq Hearings Panel dated June 28, 2024.
Outlook, Risks, and Contingencies
Monitoring Period: The Company is subject to a Mandatory Panel Monitor for a period of one year.
Delisting Risk: If the Company falls out of compliance with the Bid Price Rule during this one-year monitoring period, it will not be permitted to submit a plan of compliance or receive additional cure time. Instead, Nasdaq Staff will issue a Delist Determination Letter. The Company would then have the opportunity to request a hearing, but its securities may be delisted from Nasdaq at that time.
Investor Verification Checklist
- Verify the current trading price of SBFM to ensure it remains above the $1.00 minimum bid price requirement.
- Monitor future 8-K filings for any notices of non-compliance during the one-year Mandatory Panel Monitor period.
- Review the June 28, 2024, Hearings Panel decision for details on the prior deficiency.
- Confirm the Company's ongoing financial health through its most recent 10-Q or 10-K, as this filing contains no financial data.